Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego
The presentation will take place at the 23rd annual PepTalk conference in San Diego.
- The presentation will take place at the 23rd annual PepTalk conference in San Diego.
- The IgG-degrading enzyme of S. pyogenes (IdeS) has been approved in wild type form for use in certain kidney transplantation recipients, where IgG depletion successfully mitigates host immunity against the transplant.
- View the full release here: https://www.businesswire.com/news/home/20240116136157/en/
Figure shows IgG levels after WT IdeS in diamonds and Cyrus’ candidates in squares and triangles. - Indications such as Guillain-Barre Syndrome, Autoimmune Immune Thrombocytopenia, Idiopathic Immune Myopathies, pemphigus vulgaris, and other diseases with a poor current standard of care are under consideration.